Revenue and Adjusted EBITDA Set New Third-Quarter Records

Market Share Reaches Historic High of 17.1%

HONG KONG, Oct. 29, 2026 /PRNewswire/ -- MGM China Holdings Limited ("MGM China" or the "Company"; SEHK Stock Code: 2282) today announced the selected unaudited financial data of the Company and its subsidiaries (the "Group") for the three months (the "Period") and nine months ended September 30, 2026.

During the period, Macau witnessed sustained growth in tourist arrivals, welcoming an average of 122,139 visitors daily, an 8% increase year-on-year. Daily gross gaming revenue ("GGR") reached MOP655 million, down 4% from last year, due to the temporary impact of the World Cup tournaments on the broader market.

• MGM China continued to outperform the industry. Daily visitation across the Company's properties rose by 10% year-on-year, while daily GGR surged 5% compared to the same period last year. Notably, Mass GGR (including slot operations) also achieved a 5% year-on-year increase, reflecting the Company's strong positioning in high-value segments.
• Revenue for the Period grew by 5% year-on-year to approximately HK$8.9 billion. The Group reported adjusted EBITDA of approximately HK$2.4 billion. Both revenue and adjusted EBITDA represent all-time highs for any third-quarter period.
• The Group's market share escalated to a new record of 17.1%, with MGM COTAI securing a 10.5% share and MGM MACAU holding 6.6%.
• Occupancy climbed to 94.1% during the Period, up from 93.5% in the prior-year period.
• On a property basis, MGM COTAI generated revenue of approximately HK$5.4 billion for the Period (2025: HK$5.1 billion), and adjusted EBITDA of approximately HK$1.52 billion (2025: HK$1.46 billion). MGM MACAU recorded revenue of approximately HK$3.5 billion for the Period (2025: HK$3.4 billion), and adjusted EBITDA of approximately HK$865 million (2025: HK$914 million).
• The Group maintained a healthy financial position. As of September 30, 2026, the Group had a total liquidity of approximately HK$25.6 billion, comprised of Bank balances and cash and undrawn revolver.

This positive momentum carried into the fourth quarter, with property visitation during the October Golden Week holiday surged by 10% year-on-year.

Kenneth Feng, Chief Executive Officer of MGM China said: "The higher-end market segment continues to drive growth. The positive response to our refurbished products and premium spaces underscores our team's deep understanding of the Macau market and our ability to anticipate our customers' evolving tastes."

Following the suite conversion at MGM COTAI earlier this year, the Group has commenced the renovation project of approximately 100 suites at MGM MACAU.

"This initiative will further optimize our assets to enhance competitiveness and solidify the complementary positioning of our portfolio - establishing MGM MACAU as the premier venue on the Peninsula and MGM COTAI as the preferred destination for premium travelers. We are fully committed to supporting Macau's development into a world-class, diversified tourist destination," said Kenneth Feng.

About MGM China Holdings Limited

MGM China Holdings Limited (HKEx: 2282) is a leading developer, owner and operator of gaming and lodging resorts in the Greater China region. We are the holding company of MGM Grand Paradise, SA which holds one of the six gaming concessions to run casino games in Macau, and MGM Hospitality Asia Pacific Limited, which conducts its hospitality business through its wholly owned subsidiary MGM Hospitality Group (Asia Pacific) Limited and its subsidiaries. MGM Grand Paradise owns and operates MGM MACAU, the award-winning premium integrated resort located on the Macau Peninsula and MGM COTAI, a contemporary luxury integrated resort in Cotai. For more information about MGM China Holdings Limited, please visit the Company's website at https://en.mgmchinaholdings.com/.

MGM China is majority owned by MGM Resorts International (NYSE: MGM) one of the world's leading global hospitality companies, operating a portfolio of destination resort brands including Bellagio, ARIA, MGM Grand, Mandalay Bay and Park MGM. For more information about MGM Resorts International, please visit the Company's website at www.mgmresorts.com.

收入及經調整EBITDA再創第三季新高

市場份額達17.1%歷史高位

香港2026年10月29日 /美通社/ -- 美高梅中國控股有限公司（「美高梅中國」或「本公司」；香港聯交所股份代號：2282）今天公佈本公司及其附屬公司（「本集團」）截至2026年9月30日止三個月（「本期間」）及九個月的未經審核節選財務數據。

澳門入境旅客人次在期內持續增長，平均每日接待122,139名旅客，同比增加8%。期間適逢世界盃賽事，對博彩需求造成分流影響，每日博彩毛收入較去年下降4%至6.55億澳門幣。

• 美高梅中國的表現繼續優於同業。每日旅客量同比上升10%，每日博彩毛收入較去年同期上升5%。而中場博彩毛收入（包括角子機業務）亦實現同比增長5%，反映本公司在高端市場的良好定位。
• 本期間收入按年增長5%至約89億港元。本集團錄得經調整EBITDA為約24億港元。收入及經調整EBITDA均創下歷來第三季新高。
• 本集團的市場份額上升至17.1%的新紀錄，美獅美高梅取得10.5%的份額，澳門美高梅則持有6.6%的份額。
• 酒店入住率由去年同期的93.5%升至本期間的94.1%。
• 按物業劃分，美獅美高梅於本期間的收益為約54億港元（2025年：51億港元），而經調整EBITDA為約15.2億港元（2025年：14.6億港元）。澳門美高梅於本期間錄得收入約35億港元（2025年：34億港元），而經調整EBITDA為約8.6億港元（2025年：9.1億港元）。
• 本集團維持穩健財務狀況。截至2026年9月30日，本集團的總流動資金為約256億港元，包括銀行結餘及現金及循環信貸融通的可供動用借款額。

該正面勢頭延續至第四季，十月黃金週假期期間的酒店訪客量按年增加10%。

美高梅中國首席執行官馮小峰表示：「高端市場分部持續驅動業務增長。客戶對本集團翻新高端產品的反應正面，不僅印證了團隊對澳門市場的深刻洞察，更彰顯了我們前瞻客戶品味演變的卓越能力。」

繼美獅美高梅於今年早前完成套房改裝後，本集團已於澳門美高梅展開約100間套房的翻新項目。

「本集團希望透過此舉進一步優化資產組合、提升核心競爭力，並鞏固旗下物業的互補定位，令澳門美高梅成為半島地標，美獅美高梅則成為高端旅客的首選目的地。我們全力支持澳門發展，推動其轉型為世界級多元化旅遊目的地。」馮小峰表示。

關於美高梅中國控股有限公司

美高梅中國控股有限公司（股份代號：2282）簡稱美高梅，為大中華地區領先的娛樂場博彩度假酒店發展商、擁有者和運營商之一，是美高梅金殿超濠股份有限公司及MGM Hospitality Asia Pacific Limited 的控股公司。美高梅透過 MGM Hospitality Asia Pacific Limited 的全資附屬公司美高梅亞太酒店集團及其附屬公司經營酒店運營業務。美高梅金殿超濠持有澳門經營博彩業務特許權，現時擁有及經營兩家酒店：澳門美高梅位於澳門半島、是屢獲殊榮的豪華綜合度假酒店；而位於澳門路氹城的美獅美高梅為一現代豪華綜合度假酒店。有關美高梅中國控股有限公司的詳情，請瀏覽 https://cn.mgmchinaholdings.com 。

美高梅中國控股有限公司主要由美高梅國際酒店集團（MGM Resorts International）擁有（紐約證券交易所代號：MGM）。美高梅國際酒店集團是世界領先的全球酒店及餐飲款待公司，其轄下的度假酒店項目包括百樂宮大酒店（Bellagio）、亞利亞（ARIA）、美高梅大酒店（MGM Grand）、曼德拉灣大酒店（Mandalay Bay）及Park MGM。有關美高梅國際酒店集團的詳情，請瀏覽 www.mgmresorts.com 。

SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- At the 2026 European Society for Medical Oncology (ESMO) Congress, 3SBio presented long-term follow-up results from a Chinese Phase II clinical study of SSGJ-707 combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The steadily growing efficacy benefit not only showed a significant improvement in objective response rate (ORR) versus the data first disclosed at last year's SITC (Society for Immunotherapy of Cancer) Annual Meeting, but also delivered excellent median progression-free survival (mPFS) of 13.6 and 13.8 months in squamous and non-squamous NSCLC, respectively—adding strong clinical evidence for this China-developed, bispecific antibody that has been out-licensed to a global partner.

Main Text

The updated poster reports long-term follow-up data from the Phase II study of tivunatamig (PF-08634404/SSGJ-707) combined with chemotherapy as a first-line treatment for advanced NSCLC in China. A total of 261 patients were enrolled, including 122 with non-squamous (nsq) NSCLC and 139 with squamous (sq) NSCLC. 50% of patients were aged ≥65 years, 80% had a history of smoking, and more than 40% had a PD-L1 tumor proportion score (TPS) < 1%.

At the selected dose of 10 mg/kg Q3W, the confirmed objective response rate (cORR) for tivunatamig combined with carboplatin + paclitaxel in squamous NSCLC (sq-NSCLC) was 80.7% (vs. 67.7% in the control group), while the cORR for tivunatamig combined with carboplatin + pemetrexed in non-squamous NSCLC (nsq-NSCLC) was 77.5% (vs. 44.7% in the control group).

The poster disclosed the median PFS data for tivunatamig combined with chemotherapy, with the data cutoff date updated to August 6, 2026. Median PFS was 13.6 months in squamous NSCLC versus 8.3 months in the control group, and 13.8 months in non-squamous NSCLC versus 9.7 months in the control group. Although no head-to-head comparison is available, the mPFS for SSGJ-707 is the longest reported to date among PD-1/VEGF bispecific antibodies.

Furthermore, compared with the abstract data at the February cutoff, the extended follow-up shows that overall PFS has continued to improve, with tivunatamig demonstrating a positive signal of "longer follow-up, more robust efficacy signal." This pattern of sustained benefit with prolonged follow-up carries important positive implications: on one hand, it indicates that the high response rate is not a transient effect seen in short-term evaluation and that responses are durable; on the other hand, the treatment group's advantage has not narrowed over time but the benefit has sustained. For a Phase II study, this is a key positive signal supporting subsequent confirmatory Phase III trials.

Additionally, the ctDNA clearance analysis presented in the poster is another differentiating highlight of the study. Among 126 patients with detectable baseline ctDNA who completed paired sampling, 61.9% achieved ctDNA clearance at C3D1 (Cycle 3 Day 1, approximately 9 weeks). Updated follow-up data showed that median PFS in the ctDNA-clearance population reached 16.4 months, significantly longer than the 9.6 months in the non-clearance population.

Unlike the macroscopic tumor lesion shrinkage observed on imaging, ctDNA clearance points to the microscopic level: the DNA burden from tumor cells in the blood has dropped below the limit of detection. ctDNA clearance is a molecular signal of rapid, deep tumor killing by the drug, and the significantly longer median PFS in the ctDNA-clearance population also suggests it could serve as an early predictive biomarker for treatment benefit. Looking across the PD-1/VEGF bispecific antibody landscape, the uniqueness of SSGJ-707 combined with chemotherapy lies in the early observation of ctDNA clearance and the outstanding mPFS advantage in this population; this early molecular deep response implies the potential for superior long-term survival.

In terms of safety, the incidence of ≥ Grade 3 treatment-related adverse events (TRAEs) with tivunatamig combined with platinum-based chemotherapy was broadly comparable to the tislelizumab control group. Since the SITC data disclosure, no new Grade 5 TRAEs were reported in the tivunatamig arm.

Overall, for the PD-1/VEGF bispecific antibody landscape, the value of this long-term data extends beyond the impressive ORR and PFS results. The combination of manageable safety and ctDNA conversion signals enables tivunatamig to establish a differentiated advantage among comparable competing products, pending further validation in Phase III studies.

Addressing Unmet Clinical Needs in Lung Cancer, Aiming to Become an IO 2.0 backbone Therapy

Lung cancer is one of the malignancies with the heaviest global disease burden. According to GLOBOCAN 2022 statistics, there are approximately 2.48 million new cases of lung cancer globally each year, with more than 1.06 million new cases in China—accounting for over 40% of the global total—and non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers.

The large patient population has made the first-line advanced NSCLC landscape a highly competitive arena for both Chinese and global pharmaceutical companies. For a long time, this field has faced three challenges: the efficacy of existing immunotherapy combinations is approaching a plateau, anti-angiogenic regimens are underused in the lung squamous carcinoma population, and multi-drug combination regimens are cumbersome to administer—all areas of continuous industry effort. As described in the mechanism section of the abstract, by enhancing the inhibition of VEGF and the synergistic binding with PD-1, the agent effectively activates immune responses in the tumor microenvironment, achieving efficacy improvement under a safety profile. The PD-1/VEGF bispecific antibody is a crucial component of the IO 2.0 paradigm.

Latest Development Status of tivunatamig (PF-08634404/SSGJ-707)

Tivunatamig (PF-08634404/SSGJ-707) was independently developed by 3SBio. In 2025, 3SBio granted Pfizer the global development and commercialization rights for SSGJ-707, with a total potential transaction value exceeding $6 billion. The $1.4 billion upfront payment and $100 million equity investment set a new record for the largest upfront payment in a single out-licensing transaction for a Chinese innovative drug. Consequently, SSGJ-707 continues to attract significant industry attention and is regarded as a highly promising candidate among next-generation tumor immunotherapies.

Since Pfizer took over the program, multiple global pivotal Phase III studies and indication-exploring Phase I/II studies of tivunatamig (PF-08634404/SSGJ-707) are currently underway. According to information disclosed by the company at recent industry conferences, tivunatamig has registered 11 international clinical trials and is being evaluated at more than 1,500 medical institutions globally.

These long-term follow-up data represent an important step in the global validation journey of China's innovative drugs.

A series of milestones traces the growth trajectory of SSGJ-707: securing clinical value through regulatory milestones, opening global pathways through BD collaboration, continuously generating efficacy evidence from the clinical program, and advancing global validation with high-density investment from a multinational pharmaceutical company. The long-term follow-up data announced at this ESMO Congress is the latest link in this trajectory—with PFS standing at the forefront among comparable Phase II studies, leaving room for differentiation in subsequent confirmatory Phase III studies. As a landmark project for the out-licensing of Chinese innovative drugs, its subsequent Phase III data will not only determine the commercial success of this bispecific antibody itself, but will also provide an important reference point for the PD-1/VEGF bispecific antibody landscape and the global development of Chinese innovative drugs.

CAIRO, Oct. 28, 2026 /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec" or "the Company") released Sinopec's Sustainability Report in Africa (2021-2025) in Cairo on October 25 which highlights five years of progress in energy cooperation, environmental protection, community development, and cultural exchange. The Company also introduced its global sustainability communication brand, WE17. The report shows that Sinopec implemented 33 projects across 16 African countries between 2021 and 2025, with cumulative investment exceeding US$5.7 billion and total tax payments and social responsibility contributions surpassing US$4 billion over the same period. In 2025, its operations directly created 16,000 local jobs.

Zhao Liuqing, Minister Counselor for Economic and Commercial Affairs at the Chinese Embassy in Egypt, addressed the event and noted that 2026 marks the 70th anniversary of diplomatic relations between China and Egypt and of the establishment of diplomatic relations between China and African countries. Mr. Zhao described Sinopec's activities in Egypt as an example of the China-Egypt comprehensive strategic partnership and a contribution to stronger people-to-people ties. Magdy Amer, board member of the Egypt-China Friendship Association and former Egyptian ambassador to China, also delivered remarks recognizing Sinopec's contributions to economic and social development.

Wei Dong, Managing Director of Sinopec Africa Office, presented the report and reaffirmed the Company's commitment to leveraging its integrated industrial capabilities, increasing investment in quality resources, and balancing economic performance with ecological protection and community well-being. He also emphasized Sinopec's continued participation in Africa's industrialization and public service development.

Sinopec expands energy cooperation and environmental protection

The sustainability report documents Sinopec's activities in oil and gas exploration, engineering services, refining, energy trade, and renewable energy. Sinopec is exploring wind and solar alternatives for oilfield operations in the Western Desert of Egypt through its partnership with Apache Corporation. At the Sinopec-Apache project in Egypt, gas flaring had been reduced by more than 60% by the end of 2025 through energy efficiency and gas recovery measures.

Additionally, Sinopec participates in five offshore exploration and development blocks in Angola and maintains long-term energy cooperation with Algeria. Its renewable energy activities include Ethiopia's Adama Wind Power Project, which meets approximately 20% of the capital's electricity demand, and a geothermal pipeline project that supports clean electricity generation in Kenya. Environmental initiatives include planting over 7,000 mangroves in Angola and deploying ultra-low-noise intelligent drilling rigs in Uganda which have reduced carbon emissions by more than 90% compared with conventional rigs.

Continued investment in communities and cultural exchange

Sinopec's community programs focus on employment, vocational training, education, healthcare, and infrastructure. A welding training initiative in Uganda has equipped 60 local workers with internationally recognized certifications. Across Africa, the Company has helped with the construction of more than 70 water supply plants and installation of over 4,300 kilometers of water pipelines.

In Egypt, an education-assistance initiative has supported the construction of 201 girls' schools, providing educational opportunities for over 15,000 students. Cultural exchange programs include the "Silk Road Book House - China Bookshelf" initiative in Egypt, Algeria, and Cameroon, as well as cultural exchange activities for young people.

Sinopec launches WE17

The event also saw the introduction of Sinopec's global sustainability communication brand, WE17, under the slogan "Together for Better." It is aligned with the United Nations' 17 Sustainable Development Goals and focuses on the three themes of Clean, which represents environmental responsibility, Care, which emphasizes community well-being, and Culture, which promotes cross-cultural exchange.

Approximately 100 representatives from government, business, academia, and the media attended the event.

For more information, visit SINOPEC's official website.

Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach

MADRID and SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's pharmaceutical industry, Hengrui Pharma presented 64 research findings at this year's congress, marking a new record for the company and showcasing the strength and clinical potential of Chinese pharmaceutical innovation on the international stage.

Broad Oncology Research Portfolio Showcases Chinese Innovation on the Global Stage

Hengrui has long been committed to advancing cancer treatment, and its research achievements received further recognition at this year's ESMO Congress. A total of 64 oncology research studies were accepted for presentation, including three Proffered Papers, three Rapid Oral presentations, 32 Posters and 26 e-Posters. The research covered more than ten cancer areas, including gastrointestinal, lung and breast cancers, gynecological and genitourinary cancers, and other tumor types, as well as supportive care. It involved 21 innovative drugs in China, including nine approved products and 12 investigational candidates. ^[1]

Hengrui Oncology has participated in the ESMO Congress for 11 consecutive years, beginning in 2016. Since 2023, the company has presented nearly 200 research findings at the congress, demonstrating its strength in oncology innovation and highlighting its role in bringing Chinese pharmaceutical innovation to the international stage.

Dr Karen Atkin, Head of Global Business and Portfolio Strategy at Hengrui Pharma, said: "ESMO is an important platform for scientific exchange in oncology worldwide. We are delighted to share Hengrui's latest research and engage with peers worldwide on emerging scientific advances and potential areas of collaboration. Looking ahead, we will continue to advance our international development strategy and expand opportunities to develop our innovative medicines in partnership with international collaborators, with the aim of bringing more treatment options to patients worldwide."

From Participation to Real Impact: Advancing Cancer Treatment Through High-Value Innovation

Hengrui Oncology's progress is underpinned by sustained investment in R&D. With decades of experience in oncology drug discovery and development, Hengrui Pharma has established an integrated four-part approach to innovative therapies, encompassing precision therapy, immunotherapy, targeted therapy and supportive care. Alongside further developing established technology platforms such as antibody-drug conjugates (ADCs), Hengrui Oncology is also exploring emerging technologies, including artificial intelligence-driven drug discovery (AIDD), to integrate AI into the drug development process and improve R&D efficiency.

As of June 2026, 14 independently developed Class 1 innovative oncology medicines had been approved for marketing in China. Hengrui Oncology has established a comprehensive portfolio spanning seven major disease areas, oncology supportive care, and areas of substantial unmet medical need. It also has around 50 innovative assets in clinical development, with around 100 clinical studies underway worldwide. Several products have received U.S. FDA Orphan Drug and Fast Track designations.

As a key driver of Hengrui's innovation-led transformation, oncology is one of the company's most research-intensive business areas and among those with the most established pathways for translating innovation into commercial products. In 2025, sales of innovative oncology medicines accounted for 81.02% of Hengrui's total innovative medicine sales revenue,^[2] reflecting the company's continued efforts to translate innovation into both clinical and commercial value.

Building on its established commercial foundation, Hengrui Oncology is actively expanding its presence in the global innovation landscape. Through its network of 15 R&D sites across Asia, Europe, North America, Australia and other key markets, the company is advancing international multicenter clinical trials for multiple innovative programs and developing R&D and regulatory capabilities in major global markets. Hengrui Pharma is also steadily pursuing a range of collaboration models, including out-licensing, co-development, and NewCo partnerships, to support international collaboration on oncology innovation projects and accelerate the expansion of innovative therapies into overseas markets.

A patient-focused philosophy remains central to Hengrui Oncology's R&D. Looking ahead, Hengrui Oncology will continue to drive innovation at its source and bring more Chinese-developed medicines to international markets, expanding treatment options for cancer patients worldwide and contributing Chinese innovation and expertise to the global fight against cancer.

References:

1. ESMO Congress Official Website: https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/session
2. Hengrui's 2025 Annual Report: http://static.sse.com.cn/disclosure/listedinfo/announcement/c/new/2026-03-26/600276_20260326_RAEC.pdf

About Hengrui Pharma

Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Hengrui Oncology

Hengrui Oncology is one of Hengrui Pharma's core strategic business areas. Following decades of development, it has established a comprehensive portfolio spanning seven major disease areas, including gastrointestinal and breast cancers, as well as oncology supportive care. As of June 2026, 14 independently developed Class 1 innovative medicines, including AiRuiKa^® (Camrelizumab for Injection), HengQu^® (Herombopag Olamine Tablets) and AiWeiDa^® (Trastuzumab Rezetecan for Injection), had been launched in China. Supported by its global R&D system and a range of international collaborations, Hengrui Oncology is accelerating its transition from innovation in China to innovation for the world, offering more precise, accessible and high-quality treatment options for patients with cancer.

For more information, please visit: www.hengrui.com

BEIJING, Oct. 27, 2026 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the Third Quarter 2026 ended September 30, 2026, before the U.S. market opens on November 16, 2026. Baidu's management will hold an earnings conference call at 7:30 AM on November 16, 2026, U.S. Eastern Time (8:30 PM on November 16, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of "Baidu Inc. Q3 2026 Earnings Conference Call". Please follow the steps to enter your registration details, then click "Register". Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10057872-oyt4z8.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until November 24, 2026:
US: 1 855 883 1031
Replay PIN: 10057872

About Baidu

Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under "BIDU" and the HKEX under "9888." One Baidu ADS represents eight Class A ordinary shares.

成都2026年10月26日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)宣佈，在西班牙馬德里舉行的2026年歐洲腫瘤內科學會(ESMO)大會上，大連醫科大學附屬第二醫院李曼教授以快速口頭報告形式公佈了蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊^®) III期OptiTROP-Breast01研究總生存期(OS)最終分析結果(4639RO；快速口頭報告 | 乳腺癌-晚期階段)。結果顯示，在既往接受過治療的局部復發或轉移性三陰性乳腺癌(TNBC)患者中，蘆康沙妥珠單抗(sac-TMT)較醫生選擇的化療持續帶來生存獲益。這一結果亦同步刊登發表於國際權威腫瘤學期刊《腫瘤學年鑒》(Annals of Oncology，影響因子=80.4)。

該研究的最終無進展生存期(PFS)分析和期中OS分析結果已於2024年美國臨床腫瘤學會(ASCO)年會發表。經盲態獨立中心審評(BICR)評估，蘆康沙妥珠單抗(sac-TMT)較化療顯著改善無進展生存期(PFS)(HR 0.32；95% CI 0.24-0.44)；在預設期中OS分析中，蘆康沙妥珠單抗(sac-TMT)較醫生選擇的化療顯示具有統計學意義的OS獲益(HR 0.53；95% CI 0.36-0.78)。基於此，蘆康沙妥珠單抗(sac-TMT)已於2024年11月獲中國國家藥品監督管理局(NMPA)批准，用於治療既往至少接受過2種系統治療(其中至少1種治療針對晚期或轉移性階段)的不可切除的局部晚期或轉移性TNBC成人患者。

本次OS最終分析結果表明，中位隨訪29.4個月時，結果延續了預設期中分析已證實的具有統計學意義的OS獲益：

• 死亡風險降低40%，蘆康沙妥珠單抗(sac-TMT)較化療的OS HR為0.60(95% CI 0.45-0.80)，兩組中位OS分別為14.7個月和9.9個月。
• 蘆康沙妥珠單抗(sac-TMT)組30個月 OS 率達26.8% ，化療組為13.2%，生存獲益持續。
• 校正後死亡風險降低45%：化療組中27.8%的患者接受了後續抗體偶聯藥物(ADC)治療，採用預設的等級結構保留失效時間 (RPSFT) 模型校正後，蘆康沙妥珠單抗(sac-TMT) 的OS獲益仍然保持，OS HR為 0.55 (95% CI 0.39-0.73), 兩組中位OS分別為14.7個月和9.4個月。

安全性方面，延長隨訪後未發現新的安全性信號。兩組治療相關不良事件(TRAEs)主要為血液學毒性，導致永久停藥的TRAE發生率均為1.5%。

大連醫科大學附屬第二醫院李曼教授表示：「對於接受過多線治療且治療選擇有限的晚期TNBC患者，蘆康沙妥珠單抗(sac-TMT)單藥治療相對化療實現了顯著的生存獲益。此外，基於良好的療效及安全性，該藥物真正達到了延長生存時長、提升生存質量的雙重臨床獲益，有助於填補後線TNBC患者亟待滿足的治療需求。」

OptiTROP-Breast01 研究：

OptiTROP-Breast01是一項隨機、多中心、開放標籤 III 期研究，共納入263例患者，按1︰1隨機接受蘆康沙妥珠單抗(sac-TMT)或醫生選擇的化療。主要終點為BICR評估的PFS，OS為關鍵次要終點。截至數據截止日期(2025 年 9 月 17 日)，中位隨訪時間為 29.4 個月。研究表明，蘆康沙妥珠單抗(sac-TMT)相較於化療顯示出具有臨床意義且持續的OS 獲益；預設亞組的OS獲益總體一致，包括既往接受過程序性細胞死亡蛋白(PD-1)/程序性細胞死亡配體1(PD-L1)抑制劑治療及人類表皮生長因子受體2(HER2)低表達患者。

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊^®)

作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型靶向人滋養細胞表面抗原2(TROP2)的ADC，針對非小細胞肺癌(NSCLC)、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單克隆抗體沙妥珠單抗形成不可逆結合，另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑有效載荷(KL610023)pH敏感裂解，從而最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。

於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前，蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市，分別用於：1)既往至少接受過2種系統治療(其中至少1種治療針對晚期或轉移性階段)的不可切除的局部晚期或轉移性TNBC；2)經表皮生長因子受體-酪氨酸激酶抑制劑(EGFR-TKI)和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的激素受體陽性(HR+)且HER2陰性(HER2-) (免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲NMPA授予6項突破性療法認定。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。蘆康沙妥珠單抗(sac-TMT)的兩項新增適應症上市申請已獲NMPA受理，分別用於：1)聯合帕博利珠單抗一線治療PD-L1腫瘤比例分數(TPS)≥1%的EGFR基因突變陰性和間變性淋巴瘤激酶(ALK)陰性的局部晚期或轉移性NSCLC；2)PD-L1綜合陽性評分(CPS)<10或早期階段接受過PD-1/PD-L1抑制劑的復發或轉移性TNBC的一線治療，以上兩項申請均被納入優先審評審批程序。目前，公司已在中國開展9項註冊性臨床研究。默沙東已啟動18項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有 30 余個重點創新藥項目，其中 4 個項目 8 個適應症已獲批上市，2 個項目 3 個適應症處於 NDA 階段，10 余個項目正處於臨床階段。公司成功構建了享譽國際的專有 ADC 及新型偶聯藥物平台 OptiDC™，已有 2 個 ADC 項目 5 個適應症獲批上市，多個 ADC 或新型偶聯藥物產品處於臨床或臨床前研究階段。更多信息請訪問官網 https://kelun-biotech.com/。

TIANJIN, China, Oct. 26, 2026 /PRNewswire/ -- China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") recently hosted the second Sinopec International Catalyst Customer Conference in Tianjin under the theme "Catalyzing Collaboration, Shaping a Smarter Future." The event focused on catalyst innovations that support more efficient refining and chemical production. The conference showcased advances in technology, product development and industrial applications, connecting research with the evolving needs of customers worldwide.

The conference brought together representatives of 69 customers and partners from 24 countries and regions, including the Netherlands, Switzerland, Algeria, Brazil, Azerbaijan and South Korea. It provided a platform for exchanging technical expertise, sharing practical experience and exploring opportunities for cooperation across the refining and chemical industries.

Catalysts play a central role in petroleum refining and chemical manufacturing, helping producers improve energy efficiency, reduce carbon emissions, upgrade processes and develop new materials. As the industry pursues more sustainable production, closer collaboration among technology developers, manufacturers and customers is becoming increasingly important.

Drawing on decades of research and development, Sinopec has developed core technologies across refining and chemical catalysts. Its portfolio includes nearly 300 products across seven categories: refining, polyolefins, basic organic raw chemicals, coal chemicals, environmental protection, adsorbents and additives, and oilfield chemicals. These products support a broad range of industrial processes and applications.

Sinopec has served international catalyst markets for more than 20 years, combining products with technical services for customers in over 40 countries and regions across Asia, Africa, Europe and the Americas. Between 2021 and 2025, the company exported 14 catalyst types for the first time, including catalysts used in propane dehydrogenation, xylene isomerization and continuous catalytic reforming. It also added 13 export destinations, including Canada, the United Kingdom and Argentina.

The company's catalyst business has established trade partnerships with more than 30 countries participating in the Belt and Road Initiative. Its products and technical support help customers upgrade refining processes and improve fuel quality, contributing to the development of local refining and chemical industries.

The customer conference forms part of Sinopec's efforts to strengthen technical exchanges and align catalyst development with industrial needs. The company plans to continue developing efficient catalysts that support more sustainable production, improve its global service network and work with international partners to bring technological advances into wider industrial use.

For more information, visit SINOPEC's official website.

• Launch of HKEX Artificial Intelligence Index and HKEX Semiconductor Index to provide benchmarks for two key technology themes
• HKEX continues to expand proprietary index suite and broaden coverage of emerging technology trends
• License agreement with Southern Asset Management to issue ETFs based on the HKEX Artificial Intelligence Index in Chinese Mainland

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to announce the launch of the HKEX Artificial Intelligence Index and the HKEX Semiconductor Index. These new indices further expand HKEX's proprietary index offering and provide investors with new benchmarks to capture opportunities arising from two of the most dynamic technology themes.

HKEX is also pleased to announce that it has entered into a licensing agreement with China Southern Asset Management Company Limited (Southern Asset Management) for the introduction of exchange traded funds (ETFs) based on the HKEX Artificial Intelligence Index in the Chinese Mainland. Details of the product launch will be shared in due course.

Richard Leung, HKEX Group Chief Information Officer, said: "We are delighted to be launching these new thematic indices. Artificial intelligence and semiconductors are transforming industries and becoming increasingly important drivers of growth and innovation globally. At HKEX, we are committed to continuously expanding our index suite to give investors more ways to capture these trends and participate in the growth of the region's technology ecosystem."

Mr Leung added: "We are pleased to be licensing the HKEX Artificial Intelligence Index to Southern Asset Management for ETF products in the Chinese Mainland and look forward to partnering with other market participants to develop more investment products based on our index suite, increasing investor choice and further elevating the depth and vibrancy of our markets."

Yang Xiaosong, Southern Asset Management General Manager, said: "We are honoured to be licensed by HKEX to develop an ETF tracking the HKEX Artificial Intelligence Index in the Chinese Mainland market. This is an important example of Southern Asset Management putting its international strategy into practice and serving investors' needs for diversified asset allocation. Through this collaboration, we will turn the opportunities across Hong Kong's AI value chain into an index-based tool that mainland investors can access conveniently. Looking ahead, we will continue to enrich our product offering for cross-market connectivity, build an investment bridge between the mainland and Hong Kong capital markets, and support two-way empowerment and a virtuous cycle between the technology sector and capital markets in a high-standard opening-up environment."

The HKEX Artificial Intelligence Index is designed to measure the performance of 40 Hong Kong-listed companies with high exposure to the artificial intelligence (AI) value chain. The index provides broad exposure to a five-layer AI stack across the AI ecosystem, spanning the areas including chip design, data centres, AI infrastructure, AI models, as well as software and physical applications. Constituents are selected and weighted using a fundamental-tilted approach, designed to identify companies with meaningful investment in AI research and development and capital expenditure. This offers investors with a representative benchmark for capturing the development of the Hong Kong-listed AI sector.

Meanwhile, the HKEX Semiconductor Index measures the performance of the 30 largest semiconductor-related companies listed in Hong Kong. The index captures exposure across multiple segments of the semiconductor industry, including semiconductor manufacturing, equipment, electronic components, computing hardware and storage, providing investors with a benchmark to track developments across the Hong Kong-listed semiconductor value chain. 

The launch of the two indices further strengthens HKEX's proprietary index offering and broadens its coverage of emerging technology themes, supporting the development of new index-linked investment products and providing investors with more ways to capture opportunities in Hong Kong's markets.

More information on the HKEX Artificial Intelligence Index and the HKEX Semiconductor Index, including their index methodologies, is available on the HKEX website.

About HKEX

Hong Kong Exchanges and Clearing Limited (HKEX) is a publicly-traded company (HKEX Stock Code: 388) and one of the world's leading global exchange groups, offering a range of equity, derivative, commodity, fixed income and other financial markets, products and services, including the London Metal Exchange.

As a superconnector and gateway between East and West, HKEX facilitates the two-way flow of capital, ideas and dialogue between China and the rest of the world, through its pioneering Connect schemes, increasingly diversified product ecosystem and its deep, liquid and international markets.

HKEX is a purpose-led organisation which, across its business and through the work of HKEX Foundation, seeks to connect, promote and progress its markets and the communities it supports for the prosperity of all.

www.hkexgroup.com 

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Recently, Newborn Town's game-oriented social platform TopTop has launched "Slap Showdown", an AI-powered 3D interactive mini-game developed in collaboration with Viggle, a company specializing in physics-native world models. The launch brings world model technology into social gaming, offering users a more personalized and engaging interactive experience.

Developed by TopTop and powered by Viggle's self-developed Joint Space-Time (JST) world model, "Slap Showdown" lets users turn uploaded photos into customized 3D characters and take them straight into the game.

Launched in September, "Slap Showdown" has gained particular traction in Japan, among Spanish-speaking users in North America, and across the Middle East. It is now available in multiple countries and regions worldwide.

From Better Gameplay to a Richer Ecosystem: How World Models Could Redefine Social Gaming on TopTop

In terms of gameplay, "Slap Showdown" combines AI-generated 3D characters with multiplayer interaction. Players can simply upload a photo from their phone and generate a personalized 3D character in around 30 seconds, whether it's an anime protagonist, a cyberpunk cyborg, or a LEGO minifigure. They can then bring their custom characters into the game and face off against other players in fun, interactive battles.

As players use controls such as press-and-hold, tap, and drag, the 3D characters respond with realistic, physics-based movements. This takes AI-generated characters beyond visual customization, integrating them directly into the gameplay experience.

According to TopTop's operations team, "Slap Showdown" has attracted a growing base of highly engaged, high-spending-potential players in its first month since launch. The game has recorded a 97% match completion rate, while its game-start rate has also exceeded the platform-wide average.

The depth of user engagement is further illustrated by individual player activity. One player in Japan completed 1,041 matches over 22 days, reaching a daily peak of 151 matches and averaging one match every 9.5 minutes. Another particularly avid player in Eastern Europe completed 735 matches in just 11 days, averaging 66.8 matches per day and peaking at 126 matches in a single day.

For a UGC-driven social gaming platform such as TopTop, mini-games serve as entry points and traffic drivers, while social features underpin retention and monetization. Personalized 3D avatars add another dimension to that experience. Beyond their visual appeal, they give users new ways to express themselves, interact with friends and share memorable moments. In turn, richer gameplay and more meaningful social interactions can help improve retention, attract new users and strengthen engagement across the platform.

"Slap Showdown" marks a successful step in TopTop's efforts to deepen its application of AI technology, as well as a starting point for using world models to enhance gaming and social experiences. TopTop's operations team said future game releases could make greater use of AI-powered 3D generation, extending beyond avatars to include customized environments. Existing games could also be revitalized by the introduction of new gameplay features, potentially driving stronger retention and user acquisition.

Beyond enriching gameplay, world model capabilities could also reshape social interaction itself, enabling more immersive, face-to-face experiences in virtual spaces. "We're constantly exploring how AI can transform gaming and social interaction, while bringing new energy and capabilities to our UGC ecosystem," TopTop's operations team said.

Viggle Unveils Physics-Native Model JST-2, Setting Its Sights on Becoming the Infrastructure Layer for Physical AI

The world model technology powering "Slap Showdown" is provided by Viggle.

Founded in 2022, Viggle has focused on developing physics-native world foundation models. Its self-developed JST model can generate 3D characters, motion and environments directly, providing a foundation for gaming and a growing range of AI applications.

Viggle previously attracted widespread attention with Meme Maker, its AI-powered video creation product. The tool enables users to animate static characters and generate videos by applying specified movements, making AI character animation and video creation more accessible. In August 2024, Viggle raised USD 19 million in a Series A funding round led by Silicon Valley venture capital firm Andreessen Horowitz (a16z).

However, video creation was an early application of this technology. Viggle's longer-term ambition is to make JST a foundational technology for AI-powered experiences across gaming, social platforms and other applications.

Viggle is now further expanding its technological boundaries. On 19 October, Viggle launched JST-2 in full, likening its significance for world models to GPT-2's role in the evolution of language models.

Unlike many world models that infer physical structure indirectly from pixels, JST-2 is built around a physics-native architecture designed to learn the structure and dynamics of the 3D world directly. Its underlying representation consists of units resembling digital "atoms." Each has a defined position in three-dimensional space, along with physical properties such as material, color and mass, and information describing how it moves and responds to forces. This allows the model to do more than generate convincing images. It can represent and generate 3D characters, motion and scenes with an underlying understanding of their physical properties.

To support this approach, Viggle has developed an integrated technology stack spanning tokenization, model architecture, data engine, pre-training and post-training. After four years of research and development, JST-2 can generate characters, motion and scenes within a single unified architecture.

Compared with other approaches, JST-2 also demonstrates cost efficiency. JST-2 can generate a 3D scene in seconds, at an inference cost of less than one US cent. Once created, the content can be rendered locally without repeatedly running the foundation model to generate each frame.

It is noteworthy that world model technology remains at an early stage, but Viggle is already working toward more advanced capabilities.

Its next-generation model, JST-3, is intended to become a comprehensive world simulator. Such a system could underpin future game and graphics engines, while also serving as a virtual training environment for robotics and other forms of physical AI.

The longer-term goal is for JST-3 to learn the physical rules governing its simulated world directly from data, rather than relying on rules explicitly written by developers.

For Newborn Town, its investment in and partnership with Viggle represents an important step in exploring how advanced AI can reshape social gaming, promoting a deep integration of AI technology with its business operations.

As a leading global social entertainment company, Newborn Town has continued to deepen the use of AI across key areas in recent years, including product R&D, social recommendation systems, intelligent operations, safety and risk management, and marketing and user acquisition, supporting ongoing business growth.

Meanwhile, the company also continued to invest across the AI ecosystem, backing projects in areas including world models, AI companionship, AI Agents and AI interactive gaming. These investments have further enriched its AI application ecosystem, with Viggle among the AI companies previously backed by Newborn Town.

"Slap Showdown" represents an early step in bringing world models into social gaming. For Newborn Town and Viggle, the next challenge is to turn increasingly sophisticated AI capabilities into experiences that users find genuinely engaging — and compelling enough to keep coming back.